Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.

Chromocell Therapeutics Corporation

Chromocell is a life sciences company which improves consumer products and patient lives through breakthrough science and technologies. Chromocell is focused on the discovery and development of therapeutics and flavors through the use of pioneering Chromovert® technology. Chromovert technology enables Chromocell to use rare cells ideally suited for effective high-throughput screening. Chromocell’s therapeutics pipeline is currently focused on analgesics and rare diseases, where Chromovert technology has proven highly effective in the rapid identification of potential new drug candidates. In our flavors and nutrition business, Chromocell works with global consumer goods companies to discover and develop flavor ingredients and natural taste enhancers. The technology is applicable to all areas of taste sensations as well as aroma and fragrance enhancer discovery.

	Dec '21	Dec '22	Dec '23
revenue
cost of revenue	209.05K -	391.73K 87.39%	2.58M 558.47%
gross profit	-209.05K -	-391.73K 87.39%	-2.58M 558.47%
selling and marketing expenses
general and administrative expenses	629.95K -	1.93M 205.81%	4.28M 122.32%
selling general and administrative expenses	629.95K -	1.93M 205.81%	4.28M 122.32%
research and development expenses	209.05K -	391.73K 87.39%	2.58M 558.47%
other expenses
cost and expenses	839.00K -	2.32M 176.30%	6.86M 196.02%
operating expenses	839.00K -	2.32M 176.30%	6.86M 196.02%
interest expense	253 -	140.43K 55,405.93%	518.51K 269.23%
ebitda	-839K -	-2.32M 176.30%	-6.86M 196.02%
operating income	-839K -	-2.32M 176.30%	-6.86M 196.02%
depreciation and amortization	839.00K -	690.45K 17.70%	6.86M 893.88%
total other income expenses net	243.61K -	-140.43K 157.64%	-518.51K 269.23%
income before tax	-595.39K -	-2.46M 312.94%	-7.38M 200.20%
income tax expense	-839.00K -	-690.45K 17.70%	-6.86M 893.88%
net income	-595.39K -	-2.46M 312.94%	-7.38M 200.20%
weighted average shs out	5.77M -	5.77M 0%	5.88M 1.91%
weighted average shs out dil	5.77M -	5.77M 0%	5.88M 1.91%
eps	-0.10 -	-0.43 330.00%	-1.26 193.02%
epsdiluted	-0.10 -	-0.43 330.00%	-1.26 193.02%

COM:CHROMOCELL

Chromocell

Last Close

0.62

21/11 18:45

Market Cap

3.73M

Beta: -

Volume Today

45.73K

Avg: -

Preview